DK1442023T3 - Crystalline sodium salt of telmisartan and its use as angiotensin antagonist - Google Patents

Crystalline sodium salt of telmisartan and its use as angiotensin antagonist

Info

Publication number
DK1442023T3
DK1442023T3 DK02777305T DK02777305T DK1442023T3 DK 1442023 T3 DK1442023 T3 DK 1442023T3 DK 02777305 T DK02777305 T DK 02777305T DK 02777305 T DK02777305 T DK 02777305T DK 1442023 T3 DK1442023 T3 DK 1442023T3
Authority
DK
Denmark
Prior art keywords
telmisartan
sodium salt
crystalline sodium
angiotensin antagonist
angiotensin
Prior art date
Application number
DK02777305T
Other languages
Danish (da)
Inventor
Kai Donsbach
Irmgard Hof
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1442023(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1442023T3 publication Critical patent/DK1442023T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DK02777305T 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and its use as angiotensin antagonist DK1442023T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (en) 2001-10-31 2001-10-31 Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
PCT/EP2002/011394 WO2003037876A1 (en) 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Publications (1)

Publication Number Publication Date
DK1442023T3 true DK1442023T3 (en) 2007-11-05

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02777305T DK1442023T3 (en) 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and its use as angiotensin antagonist

Country Status (35)

Country Link
EP (1) EP1442023B1 (en)
JP (1) JP5124076B2 (en)
KR (1) KR100929502B1 (en)
CN (1) CN100509789C (en)
AR (1) AR037148A1 (en)
AT (1) ATE370125T1 (en)
AU (1) AU2002338886B2 (en)
BR (1) BR0213568A (en)
CA (1) CA2463146C (en)
CO (1) CO5580785A2 (en)
CY (1) CY1107504T1 (en)
DE (2) DE10153737A1 (en)
DK (1) DK1442023T3 (en)
EA (1) EA007596B1 (en)
EC (1) ECSP045089A (en)
ES (1) ES2291505T3 (en)
HK (1) HK1073841A1 (en)
HR (1) HRPK20040372B3 (en)
HU (1) HUP0402391A3 (en)
IL (2) IL161165A0 (en)
ME (1) MEP43608A (en)
MX (1) MXPA04004013A (en)
MY (1) MY129741A (en)
NO (1) NO326465B1 (en)
NZ (1) NZ532716A (en)
PE (1) PE20030629A1 (en)
PL (1) PL211462B1 (en)
PT (1) PT1442023E (en)
RS (1) RS50879B (en)
SA (1) SA02230419B1 (en)
SI (1) SI1442023T1 (en)
TW (2) TWI341200B (en)
UA (1) UA82833C2 (en)
UY (1) UY27520A1 (en)
WO (1) WO2003037876A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
CA2555294A1 (en) 2004-02-11 2005-08-25 Marina Yu Etinger Candesartan cilexetil polymorphs
CN1953973A (en) * 2004-05-05 2007-04-25 特瓦制药工业有限公司 Preparation of candesartan cilexetil in high purity
EP1805146A4 (en) 2004-10-18 2009-01-14 Reddys Lab Ltd Dr Process for preparing telmisartan
CA2583694A1 (en) * 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (en) * 2008-07-29 2010-02-10 Sandoz AG Method for processing microbiologically produced cyclic oligopeptides
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CN103619556B (en) * 2011-06-24 2016-12-07 本田技研工业株式会社 Injection molding method and device thereof
CR20190057A (en) 2011-11-25 2019-04-23 Adverio Pharma Gmbh Method for producing substituted 5-fluoro-1h-pyrazolopyridines
AU2015335950B2 (en) 2014-10-21 2018-01-25 Takeda Pharmaceutical Company Limited Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl}pyrimidine-2,4-diamine
KR101872726B1 (en) * 2016-07-28 2018-06-29 주식회사 씨트리 Telmisartan methanesulfonate and pharmaceutical composition comprising the same
US10905676B2 (en) 2017-07-07 2021-02-02 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
WO2020143793A1 (en) * 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 Salts of heterocyclic compound and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
DK0883401T3 (en) * 1996-02-29 2003-05-05 Novartis Ag AT1 receptor antagonist to stimulate apoptosis
DE19901921C2 (en) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament

Also Published As

Publication number Publication date
UY27520A1 (en) 2003-05-30
HUP0402391A2 (en) 2005-03-29
TWI341200B (en) 2011-05-01
AU2002338886B2 (en) 2008-04-17
CN1578772A (en) 2005-02-09
HRPK20040372B3 (en) 2006-02-28
CA2463146A1 (en) 2003-05-08
BR0213568A (en) 2004-09-08
IL161165A0 (en) 2004-08-31
KR20050035172A (en) 2005-04-15
SI1442023T1 (en) 2007-12-31
KR100929502B1 (en) 2009-12-03
MY129741A (en) 2007-04-30
HUP0402391A3 (en) 2010-03-29
CN100509789C (en) 2009-07-08
UA82833C2 (en) 2008-05-26
ATE370125T1 (en) 2007-09-15
TWI333419B (en) 2010-11-21
TW201034664A (en) 2010-10-01
CA2463146C (en) 2011-01-25
HRP20040372A2 (en) 2004-10-31
AR037148A1 (en) 2004-10-27
WO2003037876A1 (en) 2003-05-08
TW200300082A (en) 2003-05-16
CY1107504T1 (en) 2013-03-13
NZ532716A (en) 2007-06-29
ES2291505T3 (en) 2008-03-01
EA007596B1 (en) 2006-12-29
JP5124076B2 (en) 2013-01-23
YU36304A (en) 2006-08-17
RS50879B (en) 2010-08-31
MEP43608A (en) 2011-02-10
JP2005536445A (en) 2005-12-02
EP1442023B1 (en) 2007-08-15
PL211462B1 (en) 2012-05-31
NO326465B1 (en) 2008-12-08
HK1073841A1 (en) 2005-10-21
EA200400479A1 (en) 2004-10-28
PL367477A1 (en) 2005-02-21
MXPA04004013A (en) 2004-06-18
ECSP045089A (en) 2004-06-28
CO5580785A2 (en) 2005-11-30
PT1442023E (en) 2007-09-17
EP1442023A1 (en) 2004-08-04
NO20041758L (en) 2004-04-29
IL161165A (en) 2009-12-24
PE20030629A1 (en) 2003-07-14
DE50210719D1 (en) 2007-09-27
SA02230419B1 (en) 2007-07-31
DE10153737A1 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
DK1442023T3 (en) Crystalline sodium salt of telmisartan and its use as angiotensin antagonist
ATE495731T1 (en) AMPHETAMINE SALT DELAYED RELEASE FORMULATION
DK1478629T3 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterial agents
NO20053569L (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
NO20043536L (en) Fluoro-substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists
IS7667A (en) New benzimidazole derivatives
DK1133477T3 (en) Substituted benzimidazoles and their use as pair inhibitors
IS7792A (en) Hydantoin derivatives and their use as TACE inhibitors
NO20050665L (en) Pyrrolidone derivatives as MAOE inhibitors
ATE258918T1 (en) CRYSTAL FORM ALPHA OF PERINDOPRIL-TERT-BUTYLAMINE SALT
DK1170288T3 (en) Diphenylurea derivatives and their use as alpha2 / 5-HT2c antagonists
NO20033618D0 (en) Phthalayinone-piperidino derivatives as PDE-4 inhibitors
DK1622612T3 (en) Pharmaceutical formulation of the sodium salt of telmitarsan
ATE386518T1 (en) BENZIMIDAZOLE DERIVATIVES
DK1401828T3 (en) N-Formylhydroxylamine Compounds as Inhibitors of PDF
DK1410793T3 (en) Method of administration of ibuprofen sodium
NO20032490D0 (en) Substituted 2-aniline benzimidazoles and their use as NHE inhibitors
AU2002338886A1 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
DK1600441T3 (en) Crystalline form of elrcanidipine hydrochloride for use as an antihypertensive agent
DE60327447D1 (en) PLASTER
IS7598A (en) New salts
NO20035206D0 (en) Pyrimidine derivatives useful as selective COX-2 inhibitors
DK1492796T3 (en) Substituted aminoisoxazoline derivatives and their use as antidepressants
FI20021531A (en) Procedure for masonry
NO20044302L (en) Crystalline parecoxib sodium